Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Intestinal2466 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00010 | 35255811 | BMC Gastroenterol | The effect of daily consumption of probiotic yogurt on liver enzymes, steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized clinical trial. | 2022 | Details |
| A00036 | 35249342 | Ann Palliat Med | Risk factors and correlation of colorectal polyps with type 2 diabetes mellitus. | 2022 | Details |
| A00075 | 35229847 | Food Funct | N-Acetylcysteine alleviates high fat diet-induced hepatic steatosis and liver injury via regulating the intestinal microecology in mice. | 2022 | Details |
| A00094 | 35222044 | Front Pharmacol | Antibiotic Disruption of the Gut Microbiota Enhances the Murine Hepatic Dysfunction Associated With a High-Salt Diet. | 2022 | Details |
| A00114 | 35216326 | Int J Mol Sci | New Insights in the Control of Fat Homeostasis: The Role of Neurotensin. | 2022 | Details |
| A00134 | 35212986 | Methods Mol Biol | Measurement of In Vivo VLDL and Chylomicron Secretion. | 2022 | Details |
| A00181 | 35195774 | Arch Microbiol | A review on the effect of gut microbiota on metabolic diseases. | 2022 | Details |
| A00202 | 35188038 | Scand J Gastroenterol | Non-alcoholic fatty liver disease and intestinal immune status: a narrative review. | 2022 | Details |
| A00248 | 35166723 | Clin Transl Gastroenterol | Relationship between hepatic gene expression, intestinal microbiota and inferred functional metagenomic analysis in NAFLD. | 2022 | Details |
| A00256 | 35163881 | Molecules | The Anti-Adiposity Mechanisms of Ampelopsin and Vine Tea Extract in High Fat Diet and Alcohol-Induced Fatty Liver Mouse Models. | 2022 | Details |
| A00257 | 35163821 | Int J Mol Sci | Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome. | 2022 | Details |
| A00269 | 35159371 | Cells | The Origins of NAFLD: The Potential Implication of Intrauterine Life and Early Postnatal Period. | 2022 | Details |
| A00272 | 35158328 | J Physiol Pharmacol | Current approach to hepatobiliary manifestations in inflammatory bowel disease. | 2022 | Details |
| A00280 | 35153490 | Int J Tryptophan Res | Intestinal Dysbiosis, the Tryptophan Pathway and Nonalcoholic Steatohepatitis. | 2022 | Details |
| A00288 | 35152443 | J Food Sci | Bentong ginger oleoresin mitigates liver injury and modulates gut microbiota in mouse with nonalcoholic fatty liver disease induced by high-fat diet. | 2022 | Details |
| A00332 | 35133032 | FASEB J | TCF7L2 transcriptionally regulates Fgf15 to maintain bile acid and lipid homeostasis through gut-liver crosstalk. | 2022 | Details |
| A00337 | 35129841 | Hepatol Res | The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease. | 2022 | Details |
| A00341 | 35127789 | Front Nutr | Lentinan Supplementation Protects the Gut-Liver Axis and Prevents Steatohepatitis: The Role of Gut Microbiota Involved. | 2022 | Details |
| A00363 | 35119232 | J Basic Clin Physiol Pharmacol | Is it possible to treat nonalcoholic liver disease using a flavanol-based nutraceutical approach? Basic and clinical data. | 2022 | Details |
| A00369 | 35115689 | Nat Genet | Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. | 2022 | Details |
| A00384 | 35108315 | PLoS One | Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency. | 2022 | Details |
| A00389 | 35104782 | Ecotoxicol Environ Saf | Chronic lead exposure induces fatty liver disease associated with the variations of gut microbiota. | 2022 | Details |
| A00392 | 35103461 | Minerva Endocrinol (Torino) | Akkermansia muciniphila as a novel powerful bacterial player in the treatment of metabolic disorders. | 2022 | Details |
| A00468 | 35070000 | World J Hepatol | Liver manifestations and complications in inflammatory bowel disease: A review. | 2021 | Details |
| A00469 | 35069993 | World J Hepatol | Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders. | 2021 | Details |
| A00470 | 35069992 | World J Hepatol | Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence? | 2021 | Details |
| A00472 | 35068798 | J Clin Exp Hepatol | Diagnosis and Management of Cirrhotic Cardiomyopathy. | 2021 | Details |
| A00484 | 35065293 | Biochem Biophys Res Commun | Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine. | 2022 | Details |
| A00515 | 35055177 | Int J Mol Sci | Inulin Improves Diet-Induced Hepatic Steatosis and Increases Intestinal Akkermansia Genus Level. | 2022 | Details |
| A00516 | 35054924 | Int J Mol Sci | GLP-1a: Going beyond Traditional Use. | 2022 | Details |
| A00517 | 35054847 | Int J Mol Sci | The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A00521 | 35053962 | Foods | Limosilactobacillus fermentum MG4295 Improves Hyperglycemia in High-Fat Diet-Induced Mice. | 2022 | Details |
| A00533 | 35052765 | Biomedicines | Bifidobacterium bifidum Shows More Diversified Ways of Relieving Non-Alcoholic Fatty Liver Compared with Bifidobacterium adolescentis. | 2021 | Details |
| A00534 | 35052763 | Biomedicines | Intestinal Barrier and Permeability in Health, Obesity and NAFLD. | 2021 | Details |
| A00546 | 35051605 | J Ethnopharmacol | Xiaoyao Powder in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2022 | Details |
| A00551 | 35048923 | Food Funct | Feeding of cuticles from Tenebrio molitor larvae modulates the gut microbiota and attenuates hepatic steatosis in obese Zucker rats. | 2022 | Details |
| A00564 | 35045647 | Zhonghua Gan Zang Bing Za Zhi | [Research progress of sodium butyrate in metabolic-associated fatty liver disease]. | 2021 | Details |
| A00576 | 35043829 | Sao Paulo Med J | High prevalence of functional dyspepsia in nonalcoholic fatty liver disease: a cross-sectional study. | 2022 | Details |
| A00586 | 35039476 | Cell Death Dis | Pathological and therapeutic roles of bioactive peptide trefoil factor 3 in diverse diseases: recent progress and perspective. | 2022 | Details |
| A00597 | 35035378 | Front Endocrinol (Lausanne) | Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity. | 2021 | Details |
| A00612 | 35029027 | J Cell Mol Med | Alterations of nitric oxide homeostasis as trigger of intestinal barrier dysfunction in non-alcoholic fatty liver disease. | 2022 | Details |
| A00637 | 35019905 | Biomater Sci | Biodegradable celastrol-loaded albumin nanoparticles ameliorate inflammation and lipid accumulation in diet-induced obese mice. | 2022 | Details |
| A00660 | 35011746 | J Clin Med | Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles. | 2021 | Details |
| A00663 | 35010976 | Nutrients | Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota. | 2021 | Details |
| A00669 | 35008925 | Int J Mol Sci | Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future. | 2022 | Details |
| A00670 | 35008852 | Int J Mol Sci | Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases. | 2021 | Details |
| A00688 | 35003024 | Front Microbiol | Effect of Chinese Herbal Medicine Mixture 919 Syrup on Regulation of the Ghrelin Pathway and Intestinal Microbiota in Rats With Non-alcoholic Fatty Liver Disease. | 2021 | Details |
| A00699 | 34998898 | Mol Cell Endocrinol | Ceramide signaling in the gut. | 2022 | Details |
| A00705 | 34995410 | Liver Int | Roles for the mycobiome in liver disease. | 2022 | Details |
| A00713 | 34992541 | Front Pharmacol | Diammonium Glycyrrhizinate Ameliorates Obesity Through Modulation of Gut Microbiota-Conjugated BAs-FXR Signaling. | 2021 | Details |
| A00748 | 34981123 | Biosci Rep | Tandem mass tag-based proteomics analysis of type 2 diabetes mellitus with non-alcoholic fatty liver disease in mice treated with acupuncture. | 2022 | Details |
| A00753 | 34979169 | Toxicology | Elemicin exposure induced aberrant lipid metabolism via modulation of gut microbiota in mice. | 2022 | Details |
| A00774 | 34972203 | J Crohns Colitis | Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. | 2022 | Details |
| A00787 | 34966475 | Oxid Med Cell Longev | Structural and Functional Modulation of Gut Microbiota by Jiangzhi Granules during the Amelioration of Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A00794 | 34965016 | Clin Transl Med | Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease. | 2021 | Details |
| A00797 | 34964117 | Compr Physiol | Bile Acids, Gut Microbiome and the Road to Fatty Liver Disease. | 2021 | Details |
| A00822 | 34957088 | Front Cell Dev Biol | Molecular Immune Mechanism of Intestinal Microbiota and Their Metabolites in the Occurrence and Development of Liver Cancer. | 2021 | Details |
| A00826 | 34956080 | Front Endocrinol (Lausanne) | Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | 2021 | Details |
| A00830 | 34954945 | Zhonghua Wai Ke Za Zhi | [Clinical effect of minimally invasive duodenum preserving pancreatic head resection for benign and pre-malignant lesions of pancreatic head]. | 2022 | Details |
| A00851 | 34948020 | Int J Mol Sci | The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A00854 | 34945677 | Foods | Lactobacillus plantarum MA2 Ameliorates Methionine and Choline-Deficient Diet Induced Non-Alcoholic Fatty Liver Disease in Rats by Improving the Intestinal Microecology and Mucosal Barrier. | 2021 | Details |
| A00855 | 34945573 | Foods | The Regulatory Effects of Citrus Peel Powder on Liver Metabolites and Gut Flora in Mice with Non-Alcoholic Fatty Liver Disease (NAFLD). | 2021 | Details |
| A00888 | 34940698 | Mar Drugs | Soluble Polysaccharide Derived from Laminaria japonica Attenuates Obesity-Related Nonalcoholic Fatty Liver Disease Associated with Gut Microbiota Regulation. | 2021 | Details |
| A00896 | 34938193 | Front Pharmacol | Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. | 2021 | Details |
| A00908 | 34933425 | Zhonghua Gan Zang Bing Za Zhi | [Intestinal flora polymorphisms with different lesional stages in an animal model of MAFLD]. | 2021 | Details |
| A00916 | 34931080 | Nat Metab | Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. | 2021 | Details |
| A00942 | 34923456 | Wiad Lek | INTESTINAL LESIONS OCCURRING IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AFTER SUFFERING THE COVID-19 INFECTION. | 2021 | Details |
| A00969 | 34915801 | Pharm Biol | Jiang Zhi Granule protects immunological barrier of intestinal mucosa in rats with non-alcoholic steatohepatitis. | 2021 | Details |
| A01007 | 34904045 | World J Hepatol | Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. | 2021 | Details |
| A01010 | 34904028 | World J Hepatol | Liver involvement in inflammatory bowel disease: What should the clinician know? | 2021 | Details |
| A01015 | 34903499 | Dig Liver Dis | Colonic inflammation accelerates the progression of liver disease: A protective role of dipotassium glycyrrhizate. | 2021 | Details |
| A01016 | 34902629 | Cell Mol Gastroenterol Hepatol | Escherichia fergusonii Promotes Nonobese Nonalcoholic Fatty Liver Disease by Interfering With Host Hepatic Lipid Metabolism Through Its Own msRNA 23487. | 2021 | Details |
| A01031 | 34896404 | J Hepatol | The fecal mycobiome in non-alcoholic fatty liver disease. | 2021 | Details |
| A01053 | 34887631 | World J Gastroenterol | Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach. | 2021 | Details |
| A01074 | 34877910 | Expert Rev Gastroenterol Hepatol | Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. | 2021 | Details |
| A01094 | 34870783 | J Gastrointest Cancer | The Gut Microbiome and Hepatocellular Carcinoma. | 2021 | Details |
| A01096 | 34870139 | Metabol Open | Protective effects of cerium oxide nanoparticles in non-alcoholic fatty liver disease (NAFLD) and carbon tetrachloride-induced liver damage in rats: Study on intestine and liver. | 2021 | Details |
| A01106 | 34867414 | Front Pharmacol | The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease. | 2021 | Details |
| A01109 | 34867343 | Front Pharmacol | Polygoni Multiflori Radix Praeparata Ethanol Extract Exerts a Protective Effect Against High-Fat Diet Induced Non-Alcoholic Fatty Liver Disease in Mice by Remodeling Intestinal Microbial Structure and Maintaining Metabolic Homeostasis of Bile Acids. | 2021 | Details |
| A01124 | 34862975 | FASEB J | Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling. | 2022 | Details |
| A01125 | 34862599 | Br J Pharmacol | Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota. | 2022 | Details |
| A01127 | 34862475 | Commun Biol | Hepatoprotective effects of Cassiae Semen on mice with non-alcoholic fatty liver disease based on gut microbiota. | 2021 | Details |
| A01145 | 34855819 | PLoS One | Association of small intestinal bacterial overgrowth with nonalcoholic fatty liver disease in children: A meta-analysis. | 2021 | Details |
| A01175 | 34840484 | J Clin Exp Hepatol | The Outcome after Hospital Discharge in Cirrhosis is Not Worsened with COVID-19 Infection: A Propensity Score-matched Analysis. | 2021 | Details |
| A01187 | 34835981 | Nutrients | Gut Microbiota Reshaped by Pectin Treatment Improves Liver Steatosis in Obese Mice. | 2021 | Details |
| A01191 | 34835410 | Microorganisms | Polyclonal Aptamers for Specific Fluorescence Labeling and Quantification of the Health Relevant Human Gut Bacterium Parabacteroides distasonis. | 2021 | Details |
| A01195 | 34831031 | Cells | Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01199 | 34830313 | Int J Mol Sci | Aryl Hydrocarbon Receptor (AhR) Activation by 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) Dose-Dependently Shifts the Gut Microbiome Consistent with the Progression of Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A01200 | 34830072 | Int J Mol Sci | T Cell Subsets and Natural Killer Cells in the Pathogenesis of Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01229 | 34821899 | Food Funct | Maternal sucralose exposure induces Paneth cell defects and exacerbates gut dysbiosis of progeny mice. | 2021 | Details |
| A01298 | 34798124 | Biochem Pharmacol | CYP4V2 fatty acid omega hydroxylase, a druggable target for the treatment of metabolic associated fatty liver disease (MAFLD). | 2021 | Details |
| A01302 | 34795655 | Front Microbiol | Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. | 2021 | Details |
| A01332 | 34786174 | World J Hepatol | Serum zonulin levels in patients with liver cirrhosis: Prognostic implications. | 2021 | Details |
| A01339 | 34783554 | J Agric Food Chem | Novel Sesquiterpene Glycoside from Loquat Leaf Alleviates Type 2 Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease by Improving Insulin Resistance, Oxidative Stress, Inflammation, and Gut Microbiota Composition. | 2021 | Details |
| A01345 | 34780166 | Chem Res Toxicol | Differential Roles of Water-Insoluble and Water-Soluble Fractions of Diesel Exhaust Particles in the Development of Adverse Health Effects Due to Chronic Instillation of Diesel Exhaust Particles. | 2021 | Details |
| A01352 | 34778099 | Front Cell Infect Microbiol | Gut Microbiota, Glucose, Lipid, and Water-Electrolyte Metabolism in Children With Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01355 | 34777261 | Front Endocrinol (Lausanne) | Endotoxins and Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A01368 | 34773257 | Hepatology | A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome. | 2021 | Details |
| A01373 | 34771023 | Molecules | Zinc as a Drug for Wilson's Disease, Non-Alcoholic Liver Disease and COVID-19-Related Liver Injury. | 2021 | Details |
| A01374 | 34769488 | Int J Mol Sci | The Roles of Carbohydrate Response Element Binding Protein in the Relationship between Carbohydrate Intake and Diseases. | 2021 | Details |